GH Research (NASDAQ:GHRS – Get Free Report) had its target price boosted by equities research analysts at Guggenheim from $40.00 to $46.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price objective would suggest a potential upside of 151.78% from the company’s current price.
A number of other research firms have also recently commented on GHRS. Needham & Company LLC raised their price target on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald upped their price objective on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price objective on the stock. Finally, Stifel Nicolaus set a $38.00 target price on GH Research in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.00.
View Our Latest Research Report on GHRS
GH Research Stock Performance
GH Research stock opened at $18.27 on Wednesday. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -19.23 and a beta of 1.31. GH Research has a 52-week low of $12.04 and a 52-week high of $31.44. The stock’s 50 day moving average price is $21.92 and its two-hundred day moving average price is $21.66.
GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. On average, equities research analysts forecast that GH Research will post -1.20 EPS for the current year.
Hedge Funds Weigh In On GH Research
A number of institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after purchasing an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research in the 3rd quarter valued at $82,000. Bellevue Group AG bought a new stake in GH Research during the 3rd quarter valued at $109,000. Farther Finance Advisors LLC increased its stake in GH Research by 9,720.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after purchasing an additional 9,720 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in GH Research during the 1st quarter valued at $290,000. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Further Reading
- Five stocks we like better than GH Research
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
